Cargando…
A Quantitative Process for Enhancing End of Phase 2 Decisions
The objectives of the phase 2 stage in a drug development program are to evaluate the safety and tolerability of different doses, select a promising dose range, and look for early signs of activity. At the end of phase 2, a decision to initiate phase 3 studies is made that involves the commitment of...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967501/ https://www.ncbi.nlm.nih.gov/pubmed/24683441 http://dx.doi.org/10.1080/19466315.2013.852617 |